Biocon Chief Says No Chance For Indian Firm In M&A
This article was originally published in PharmAsia News
Executive Summary
The head of India's Biocon biotechnology company says she does not anticipate ever selling her company. Kiran Mazumdar Shaw, chairman and managing director of the firm, said her emotional attachment to the company is too strong for her to consider selling out to another firm, as Ranbaxy Laboratories is doing. She said her loyalty and desire to expand the company probably result from her being a first-generation entrepreneur. It is often the following generations without an emotional attachment to a start-up that are willing to consider mergers and acquisitions, she said. She acknowledged, however, the state of flux in the biotechnology sector presents its own challenge to companies. (Click here for more
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.